Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
BOM:524548's Price-to-Peter-Lynch-Fair-Value is ranked worse than 79.88% of 164
companies
in the Healthcare Providers & Services industry
Industry Median: 1.335
vs BOM:524548: 2.38
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Sharma East India Hospitals & Medical Research (BOM:524548) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 10.52 instead of 15 in this case.
Sharma East India Hospitals & Medical Research's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
90.42
/
37.98
=
2.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sharma East India Hospitals & Medical Research Peter Lynch Fair Value Related Terms
Sharma East India Hospitals & Medical Research Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sharma East India Hospitals & Medical Research Peter Lynch Fair Value Chart
Sharma East India Hospitals & Medical Research Annual Data
BOM:524548 vs HCA, THC, EHC: Peter Lynch Fair Value Comparison
For the Medical Care Facilities subindustry, Sharma East India Hospitals & Medical Research's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sharma East India Hospitals & Medical Research Price-to-Peter-Lynch-Fair-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sharma East India Hospitals & Medical Research's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Sharma East India Hospitals & Medical Research's Price-to-Peter-Lynch-Fair-Value falls into.
Sharma East India Hospitals & Medical Research's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3.61.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of ₹37.98 mean?
Sharma East India Hospitals & Medical Research (BOM:524548) has a Peter Lynch Fair Value of ₹37.98 as of Sep. 11, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Sharma East India Hospitals & Medical Research and its competitors. According to the industry distribution chart, Sharma East India Hospitals & Medical Research ranks #131 out of 164 companies in the Healthcare Providers & Services industry, placing it in the top 79.9%.
Is Sharma East India Hospitals & Medical Research's Peter Lynch Fair Value too high?
Sharma East India Hospitals & Medical Research's current Peter Lynch Fair Value is ₹37.98. Based on the distribution chart, Sharma East India Hospitals & Medical Research ranks #131 out of 164 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sharma East India Hospitals & Medical Research has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sharma East India Hospitals & Medical Research's Peter Lynch Fair Value compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sharma East India Hospitals & Medical Research ranks #131 out of 164 companies for Peter Lynch Fair Value. This places Sharma East India Hospitals & Medical Research in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Healthcare Providers & Services company?
The median Peter Lynch Fair Value among Healthcare Providers & Services companies is 1.34, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Sharma East India Hospitals & Medical Research and its competitors. For the Healthcare Providers & Services industry, the median Peter Lynch Fair Value is 1.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sharma East India Hospitals & Medical Research's current Peter Lynch Fair Value is ₹37.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharma East India Hospitals & Medical Research stock overvalued right now?
Based on GuruFocus' analysis, Sharma East India Hospitals & Medical Research (BOM:524548) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹108.22, compared to a current price of ₹90.42 — trading 16.4% below its estimated fair value. The current Peter Lynch Fair Value is ₹37.98. Sharma East India Hospitals & Medical Research's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Sharma East India Hospitals & Medical Research (BOM:524548), the current Peter Lynch Fair Value is ₹37.98 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sharma East India Hospitals & Medical Research (BOM:524548) Overvalued in 2026?
Based on GuruFocus' analysis, Sharma East India Hospitals & Medical Research stock appears to be undervalued.
The current stock price of ₹90.42 is trading 16.4% below its estimated GF Value™ of ₹108.22.
GuruFocus considers Sharma East India Hospitals & Medical Research to be Modestly Undervalued.
Key valuation signals for BOM:524548:
Peter Lynch Fair Value: ₹37.98
GF Value™: ₹108.22 vs. price of ₹90.42 (16.4% below fair value)
No single metric tells the full story. See the BOM:524548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sharma East India Hospitals & Medical Research Ltd is engaged in service activities related to the medical and healthcare services and real estate services. It provides healthcare services through the multi-specialty hospital in the name of Jaipur Hospital in Rajasthan. It provides services like joint replacement surgery, arthroscopy, cardiothoracic and vascular surgery, interventional cardiology, such as angiography and angioplasty, neurosurgery, and others.
70GF Score
Get the complete analysis for BOM:524548
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524548 has been successfully added to your 
